-
Innovation Ranking
NewInnovation Ranking – Protagonist Therapeutics Inc
Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US...
-
Product Insights
NewNet Present Value Model: Protagonist Therapeutics Inc’s Rusfertide acetate
Empower your strategies with our Net Present Value Model: Protagonist Therapeutics Inc's Rusfertide acetate report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Protagonist Therapeutics Inc’s PN-235
Empower your strategies with our Net Present Value Model: Protagonist Therapeutics Inc's PN-235 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.Drug Operating Profit Model
-
Company Insights
Innovation and Patenting activity of Protagonist Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Protagonist Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Net Present Value Model: Protagonist Therapeutics Inc’s Rusfertide acetate
Empower your strategies with our Net Present Value Model: Protagonist Therapeutics Inc's Rusfertide acetate report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rusfertide Acetate in Polycythemia Vera
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rusfertide Acetate in Polycythemia Vera report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rusfertide Acetate in Polycythemia Vera Drug Details: PTG-300 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexmedetomidine in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexmedetomidine in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexmedetomidine in Alzheimer's Disease Drug Details: Dexmedetomidine (Igalmi) is an imidazole derivate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibrutinib in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibrutinib in Renal Cell Carcinoma Drug Details: Ibrutinib (Imbruvica) is...
-
Product Insights
Hemochromatosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemochromatosis - Drugs In Development, 2023’, provides an overview of the Hemochromatosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemochromatosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Polycythemia Vera – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycythemia Vera - Drugs In Development, 2023’, provides an overview of the Polycythemia Vera pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...